Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda.
Acceptability
Breastfeeding
Dapivirine vaginal ring
HIV prevention
Oral pre-exposure prophylaxis
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
01
07
2023
pmc-release:
01
12
2024
medline:
1
11
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
This study examines qualitative acceptability of the dapivirine vaginal ring (DVR) and oral daily pre-exposure prophylaxis (PrEP) among breastfeeding persons participating in Microbicide Trials Network 043/B-PROTECTED, a phase 3B safety and drug detectability study of DVR and oral PrEP in breastfeeding. A subsample of 52 participants were purposively sampled to participate in an in-depth interview (IDI). Breastfeeding participants found both study products to be acceptable, and easy to use. A common motivation for product use was to protect the baby from HIV, although participants' understanding of how the study drug would work to protect their babies was often unclear. While most participants did not report experiencing side effects, fears about side effects were common as both initial worries about how the study products would affect their health and the health of their baby, and increased anxiety that health issues experienced by them, or their baby were from the products.
Identifiants
pubmed: 37432541
doi: 10.1007/s10461-023-04125-w
pii: 10.1007/s10461-023-04125-w
pmc: PMC10615878
mid: NIHMS1931181
doi:
Substances chimiques
Anti-HIV Agents
0
Dapivirine
TCN4MG2VXS
Types de publication
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4114-4123Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068633
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068615
Pays : United States
Organisme : NINR NIH HHS
ID : UM1AI106707
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106707
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NINR NIH HHS
ID : UM1AI068615
Pays : United States
Organisme : NINR NIH HHS
ID : UM1AI068633
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
J Womens Health (Larchmt). 2010 Nov;19(11):2071-7
pubmed: 20849286
BMC Pregnancy Childbirth. 2019 Jan 31;19(1):53
pubmed: 30704428
AIDS Behav. 2013 Jul;17(6):2162-72
pubmed: 23080358
Matern Child Nutr. 2021 Apr;17(2):e13120
pubmed: 33325126
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):304-310
pubmed: 30844995
PLoS One. 2015 Apr 13;10(4):e0125458
pubmed: 25867624
PLoS One. 2019 Nov 8;14(11):e0224898
pubmed: 31703094
J Int AIDS Soc. 2020 Jun;23(6):e25536
pubmed: 32524700
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
N Engl J Med. 2002 Jul 18;347(3):194-9
pubmed: 12124409
AIDS. 2015 Oct 23;29(16):2161-71
pubmed: 26544581
Int J Sex Health. 2017;29(3):247-257
pubmed: 30519370
AIDS. 2018 Jul 17;32(11):1517-1525
pubmed: 29957723
Reprod Health. 2011 May 02;8:9
pubmed: 21535876
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30602513
Br J Psychiatry. 1987 Jun;150:782-6
pubmed: 3651732
J Antimicrob Chemother. 2016 Apr;71(4):1027-30
pubmed: 26679247
PLoS Med. 2016 Sep 27;13(9):e1002133
pubmed: 27676386
J Int AIDS Soc. 2020 Nov;23(11):e25634
pubmed: 33206462
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
AIDS Behav. 2021 Aug;25(8):2430-2440
pubmed: 33713213
AIDS. 2017 May 15;31(8):1159-1167
pubmed: 28441175
PLoS Med. 2016 Sep 27;13(9):e1002132
pubmed: 27676257